Study of DS-1123a in Advanced Solid Tumours

See also
Status	Clinical Trial	Phase
Terminated	`NCT02192567` - Open Label Study of DS-5573a	Phase 1
Completed	`NCT01290471` - Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors	Phase 1
Completed	`NCT02675491` - Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors	Phase 1

See also

Status

Clinical Trial

Phase

Terminated

NCT02192567 - Open Label Study of DS-5573a

Phase 1

Completed

NCT01290471 - Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors

Phase 1

Completed

NCT02675491 - Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors

Phase 1

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT02690337
Study type	Interventional
Source	Daiichi Sankyo, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	January 2016
Completion date	November 2017

Study of DS-1123a in Advanced Solid Tumours

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms